ABPI president steps down over Novo Nordisk breach of trade group's code

Pinder Sahota, who is the UK country manager of Danish diabetes care giant Novo Nordisk (NOV: N), has made the decision to resign as president of the trade body Association of British Pharmaceutical Industries (ABPI).

He chose to do this to avoid an ongoing process around a Novo Nordisk ABPI Code of Practice breach becoming a distraction from the vital work of the ABPI.

The ABPI board is due to meet next month to decide whether to expel Novo Nordisk over a “disguised” promotional campaign for its weight loss treatment liraglutide, marketed as Saxenda, which is also used in the treatment of diabetes. Saxenda poted full-year 2022 global sales of 10.7 billion kroner ($1.2 billion).